Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...

Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement; 27% of these complications developed after a year, reported Sofia ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

A few months after Sanofi and Regeneron’s Dupixent scored a new indication as the first and only medicine to treat eosinophilic esophagitis (EoE) in patients 12 and older, new late-stage trial data ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...

Credit: Getty Images. The approval was based on data from a phase 3 study that evaluated Dupixent added to low potency topical corticosteroids in children aged 6 months to 5 years with uncontrolled ...

The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis ...

Please provide your email address to receive an email when new articles are posted on . Dupixent was approved in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 ...

TRENTON, N.J. --U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent ...

Dupixent is back in the driver’s seat, reclaiming the top spot for ad impressions among Rx and over-the-counter (OTC) brands in May. The eczema and asthma drug from Sanofi and Regeneron had an ...